Research hotspots and emerging trends in targeted therapy for colorectal cancer: a bibliometric analysis (2000-2023)
- PMID: 40380023
- PMCID: PMC12084209
- DOI: 10.1007/s12672-025-02632-x
Research hotspots and emerging trends in targeted therapy for colorectal cancer: a bibliometric analysis (2000-2023)
Abstract
Background: Targeted therapy has significantly transformed the treatment landscape of colorectal cancer (CRC), enabling personalized treatment approaches and improving patient prognosis. This study employs bibliometric analysis to explore the research hotspots and development trends in the field of CRC-targeted therapy from 2000 to 2023.
Methods: Based on the Web of Science Core Collection, this study collected literature related to CRC-targeted therapy published between 2000 and 2023. CiteSpace and VOSviewer were used for data analysis, with a focus on publication trends, key contributors, and keyword co-occurrence patterns.
Results: A total of 2252 relevant articles were included, demonstrating a steady growth trend in research output. China ranked first in terms of the number of publications, while the University of Texas MD Anderson Cancer Center was identified as the institution with the highest research output. Josep Tabernero was the most prolific author in this field. Among journals, Cancers had the highest impact, while Clinical Cancer Research held a significant advantage in citation frequency. Keyword co-occurrence and clustering analysis indicated that research primarily focused on treatment strategies and precision medicine, with emerging technologies such as cell therapy and liquid biopsy garnering increasing attention.
Conclusion: This study reveals the research trends, core hotspots, and emerging directions in the field of CRC-targeted therapy, providing valuable insights for future research.
Keywords: Bibliometric analysis; Colorectal cancer; Data visualization; Targeted therapy.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: All data used in this study were downloaded from public databases; therefore, no ethical approval or informed consent was required. Consent for publication: Not applicable. Patient consent: Not applicable. Competing interests: The authors declare no competing interests.
Figures







References
-
- GBD 2017 Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):913–33. 10.1016/S2468-1253(19)30345-0. - PMC - PubMed
-
- Anthony T, Jones C, Antoine J, Sivess-Franks S, Turnage R. The effect of treatment for colorectal cancer on long-term health-related quality of life. Ann Surg Oncol. 2001;8(1):44–9. 10.1007/s10434-001-0044-2. - PubMed
-
- de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33(2):214–9. 10.1016/s0959-8049(96)00370-x. - PubMed
-
- Wang Y, Dong X, Yan S, Liu B, Li X, Li S, et al. Comparison of the long-term survival outcome of surgery versus stereotactic body radiation therapy as initial local treatment for pulmonary oligometastases from colorectal cancer: a propensity score analysis. Int J Radiat Oncol Biol Phys. 2024. 10.1016/j.ijrobp.2024.07.2324. - PubMed
LinkOut - more resources
Full Text Sources